The Consortium
The consortium consists of academic scientists with a proven track record in the synthesis, application, and testing of novel materials for bacterial detection and control. The expertise and research program include ethically approved in vitro and in vivo testing of toxicity, monitored by an ethics officer within the project.
Clinical partners (Royal Bristol Children’s Hospital, BCH) and Diakonie Clinic Siegen (DKS) will inform the consortium and ensure that the research output has clinical utility. The Academic Medical Centre (AMC) – at which the research of AMR is performed – is a research centre and hospital with expertise in infection models (in vitro and in vivo), the clinical applications of research and it is a leading developer of novel highly potent antimicrobials.
Industry partners include research-intensive SMEs (Polymun (POL), Atto-Tec (ATT)), multi-national wound dressing companies (Hartmann AG (HAR)) and advanced materials companies (SEFAR (SEF); Nanostone Water (NAN); GLATFELTER (GLA)).
Public Health England (PHE) brings specific expertise of working with government on antibiotic public policy and experience of fundamental research in biofilms and infection. LES Turkey (LES) and KWORKS (accelerator linked to KOC) will facilitate the transfer of ideas from the lab to the companies. KWORKS accelerates the momentum of innovation by enhancing the path for entrepreneurs to build sustainable, scalable, technology-based ventures by integrating early-stage companies from the idea phase into an entrepreneurial ecosystem. Our partners bring a significant patent portfolio and key industrial contacts with them, which facilitates knowledge transfer to partner industries.
We emphasise that although our final goal is ambitious, each partner contributes crucial complementary expertise and technology that significantly reduce the scientific risk and enhance the training opportunities for the ESRs.
